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A  significant proportion of the protection mediated by the immune system 
against reinfection with influenza virus is due to the presence of neutralizing 
antibody  directed against  the  hemagglutinin  (HA)  1 of influenza virus  (1-5). 
However,  little  is  understood about  the  mechanism by  which  interaction  of 
neutralizing antibody with virus results in loss of infectivity. The consensus of 
opinion has been that neutralizing antibody prevents entry of virus into suscep- 
tible cells by sterically blocking the association of virus with cellular receptors, 
but  this  has  only  been  demonstrated  with  reovirus  (6).  In  other  instances, 
attachment of poliovirus  neutralized by polyclonal (7)  and  some monoclonal 
antibodies (8) is unaffected and infectivity is lost, probably because the virus is 
unable to uncoat. Vesicular stomatitis virus, similarly neutralized, still  attaches 
to host cells (9) but, in this case, attachment is thought to be mediated by a novel 
receptor. Work carried out in this laboratory on type A  influenza viruses has 
shown that avian and human strains,  neutralized by polyclonal or monoclonal 
immunoglobulin  G  (IgG)  directed against  the  HA,  attached  to  a  variety  of 
different cell types (human foreskin fibroblasts, L cells, chick embryo fibroblasts 
[CEF] cells, and baby hamster kidney 21  [BHK-21 ] cells) at temperatures from 
4  to  37°C  with  kinetics indistinguishable  from those of nonneutralized virus 
(10-12). Moreover, the kinetics of internalization of neutralized virus, its subse- 
quent uncoating, and the transport of virion  RNA to  the nuclei of CEF and 
BHK-21 cells were indistinguishable from nonneutralized virus. From this it has 
been inferred (12)  that  loss  of infectivity results from the inhibition  of some 
subsequent stage of infection. Thus, instead of a general theory of neutralization, 
it seems that different viruses are neutralized by different mechanisms (13), 
In addition to IgG, the predominant antibody in hyperimmune or convalescent 
serum, IgA and IgM also have neutralizing ability (14), and secretory IgA (sclgA) 
in  respiratory tract secretions is believed (15,  16)  to play a  major role in  the 
resistance  to  influenza  virus  infection.  However,  there  are  no  data  on  the 
mechanisms by which these classes of antibody inactivate infectivity. In this study 
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we  have  investigated  how  scIgA  obtained  from  rat  bile  neutralizes  influenza 
virus,  scIgA reduced, but did not abolish,  the attachment of virus to BHK-21 
cells,  and  prevented  it  from being  internalized.  However, neutralizing  mono- 
meric IgA derived from scIgA by differential reduction did not inhibit attach- 
ment or internalization; in this respect, its action was indistinguishable from that 
of IgG (10,  11). 
Materials and Methods 
Viruses and Cells.  The avian strain of influenza virus A/fowl plague virus/Rostock/34 
(H7N 1) (FPV/R) was grown in the allantoic cavity of embryonated hen eggs. 32p (Amer- 
sham International plc, Amersham, England)-labeled influenza virus was prepared (12) in 
roller bottles containing 2  ×  l0  s primary CEF cells (17).  Infectivity of the  virus was 
determined by plaque assay  on CEF cell monolayers under 0.9% agar in  199 medium 
containing 5%  newborn calf serum, and expressed as plaque-forming units (PFU)/ml; 
hemagglutination was assayed using chicken erythrocytes, s2P-labeled  virus was precipi- 
tated from tissue culture fluid on ice with 60%  saturated  (NH4)2SO4 and purified by 
sucrose velocity centrifugation (18), except that no unlabeled carrier was added. PFU/ 
HA  ratios  of different  preparations  varied  from  104"s to  10  s5  but  attachment  and 
internalization of virus by BHK-21 cells were unaffected by this variation (data not shown). 
BHK-21 cell monolayers were cultivated in roller bottles in Glasgow minimum essential 
medium (Gibco-BRL Ltd., Paisley, Scotland) supplemented with 100 U penicillin, 100/~g 
streptomycin sulphate, and 0.295  mg tryptose phosphate per milliliter and 5% voi/vol 
newborn calf serum (Gibco-BRL Ltd.). When confluent, cells were removed by trypsini- 
zation (0.05% wt/vol trypsin, 0.02% wt/voi versene in phosphate-buffered saline [PBS]) 
and reseeded in roller bottles or in 5 l-mm diam Nunclon plastic petri dishes (Gibco-BRL 
Ltd.) at a concentration of 6 x  106 cells per dish. 
Antisera.  Antiserum to the HA of FPV/R was raised in rabbits by inoculation with A/ 
FPV/Dutch]27 (H7N7) (FPV/D),  which has the HA antigen closely related to that of 
FPV/R and an antigenically unrelated NA.  105 hemaglutination units (HAU) of purified 
FPV/D were injected intravenously at days 1 and 22 and serum was obtained by bleeding 
at  day  28.  A  murine  neutralizing monoclonal IgG  (HC2)  to  FPV/R  HA  was  kindly 
provided by J. J. Skehel (National Institute for Medical Research, London). As a control, 
we used another monoclonal antibody (171/7), which neutralized X49 influenza virus 
(H3N2) but not FPV/R. 
Rabbit and mouse Ig were purified by affinity chromatography on a column of protein 
A-Sepharose CL-4B (Sigma Chemical Co.,  St.  Louis, MO) and stored at -70°C.  He- 
magglutination inhibition (HI) titrations were performed as described by Webster and 
Laver (19). 
Preparation  of sclgA.  Purified  FPV/D  in  PBS  was  inactivated  with  0.0025%  beta 
propiolactone (BPL) (Sigma Chemical Co.) for 8 h at 4°C, after which BPL was renewed 
and the mixture left for 24 h.  The virus suspensions were dialyzed against PBS, and, 
when tested in embryonated eggs, contained no residual infectivity. 
4  Inactivated virus (7  ×  10  HAU/rat) was injected into the Peyer's patches of inbred 
male Wistar rats (Wistar/PC61), 10 wk old and weighing ~200 g (20). Rats were confined 
in Bollman restraining cages (21) while bile was collected over days 7-9 postinoculation, 
by cannulating the common bile duct. After removing bile salts by dialysis against 0.01 M 
Tris-HCI buffer and 0.15 M sodium chloride (pH 7.4), the bile was concentrated on an 
Amicon B15 filter (Amicon Corp., Lexington, MA). IgG was removed by passing the bile 
concentrate seven times down a protein A-Sepharose column to which scIgA does not 
bind (22). Material was stored at -70°C. 
scIgA was purified using an affinity column constructed by coupling goat anti-rat a 
chain antibody (Nordic Immunological Laboratories Ltd., Maidenhead, Berkshire, United 
Kingdom) to cyanogen bromide-activated Sepharose (Sigma Chemical Co.). 2 ml of bile 
concentrate was passed through the column in 0.01 M Tris-HCl, 0.15 M sodium chloride 
(pH 8). scIgA was eluted from the column with 0.1 M ammonium hydroxide and 0.05 M 200  NEUTRALIZATION  OF  INFLUENZA  VIRUS BY  sclgA, IgA, AND  IgG 
diethylamine (pH  11.5).  Eluted samples were neutralized with HCI, dialyzed overnight 
against  1 mM Tris-HCl, 0.05 M sodium chloride (pH 7.4), and then lyophilyzed. Purity 
of scIgA  was  monitored  by  polyacrylamide gel  electrophoresis (PAGE)  (23)  and  by 
immunodiffusion against anti-a chain antibody. 
Preparation of Monomeric IgA.  Monomeric IgA was prepared from purified sIgA by 
differential reduction with 0.01 M B-mercaptoethanol (BME) (Sigma Chemical Co.) in 0.3 
M Tris-HCl (pH 8) for 1 h at 25°C. After dialyzing overnight against  1 mM Tris-HCl, 
0.015 M sodium chloride pH 7.4), IgA was separated from the secretory component (SC) 
and J  chain by affinity chromatography on an anti-a chain column as described above. 
The SC andJ chain emerged in the void volume and IgA monomers were eluted as before 
and lyophilyzed. IgA was characterized by PAGE and by imrnunodiffusion against anti-a 
chain antibody. 
Attachment of Neutralized and Nonneutralized s2P-labeled FPV/R to BHK-21 Cells.  The 
attachment of nonneutralized and neutralized s~P-labeled  FPV/R to BHK-21 cells was 
measured as described previously (10, 11). Virus was first incubated for 1 h at 25°C with 
neutralizing Ig, bile concentrate, or an equivalent mass of Ig from preimmune sources. 
100-#1 volumes of virus-Ig mixtures were inoculated onto monolayers of BHK-21 cells in 
plastic petri dishes, held on ice to give a temperature at the monolayer surface of 4°C, 
unless otherwise stated. This temperature prevents virus-directed macromolecular synthe- 
sis (24).  At the required times monolayers were rinsed three times with cold PBS and 
removed by scraping. Radioactivity associated with cells and washes  was determined by 
binding to Whatman DE81  filter discs, which were washed successively  in sodium dihy- 
drogen  orthophosphate (three times),  water,  and  ethanol.  This represents n~P-labeled 
virion RNA (lipids and proteins do not bind). 
Assay for the Uptake of Virion  RNA into Nuclei.  Cells  were fractionated by removing 
cytoplasm from cell monolayers by incubating for two successive  periods of 5  rain,  in 
0.5%  Nonidet P-40 (NP-40) (BDH Pharmaceuticals Ltd.,  London) in 0.25  M sucrose, 
0.01 M Tris-HCl (pH 7.4), 1 mM MgCI2 (11, 25) on ice. Nuclei remained attached to the 
petri dish and were scraped into the same buffer without NP-40, rinsed vigorously on a 
vortex mixer, and then pelleted at 150 g for 5 rain at 4°C. The supernatant was pooled 
with  the  cytoplasmic fraction.  This  method gives a  high  yield of nuclei  that  have a 
cytoplasmic contamination of only 5% (11).  Uptake of 32P-virion RNA into nuclei was 
measured by inoculating monolayers with nonneutralized or neutralized virus and frac- 
tionating cells at intervals. Radioactivity was collected as before using Whatman DE81 
filters.  This procedure provides a  measure of the  early stages  of infection, including 
uncoating and transport to the nucleus of the uncoated virion RNA (25). 
Proteinase  K  Removal  of 3~P-labeled Virus Attached  to  the  Cell  Surface.  Preliminary 
experiments showed that incubation with 2 ttg/ml proteinase K (sp act, 20 Anson units/ 
g;  BDH  Pharmaceuticals  Ltd.)  for 60  rain  at  4°C,  removed 85%  of the  ~SI-labeled 
concanavalin A  bound to BHK-21 cells.  The same concentration of proteinase K also 
removed infectious virus from BHK-21 cells, as measured by a reduction in the number 
of  plaques compared with nontreated cells. To determine the percentage of virus attached 
to BHK-21 cells, 32P-labeled virus-antibody mixtures were incubated with monolayers for 
2 h, and cells were then rinsed three times with cold PBS and incubated at 4°C with 500 
~! proteinase K. After 60 min, the enzyme solution was removed and pooled with two 
subsequent  washes  of 250  #1  PBS.  The  cells  were  then  fractionated into  nuclei  and 
cytoplasm and radioactivity determined as before. 
Results 
Preliminary  Detection  and  Characterization  of Antiviral  Activity  in  Bile.  Bile 
concentrate from immunized rats had a  titer of 1,800  HI units/ml,  which was 
unaffected by the removal of IgG by protein A-Sepharose chromatography. The 
presence of IgA was confirmed by double immunodiffusion in agar with anti-rat 
IgA.  No  IgM  was  detected  by immunodiffusion.  Bile concentrate neutralized 
98.5%  of  107  PFU  FPV/R  (H7N1)  but  failed to  neutralize another  strain  of TAYLOR  AND  DIMMOCK  201 
influenza virus, A/WSN (H 1N 1). Bile concentrate from nonimmunized rats had 
no antiviral activity. 
Our previous studies (11) showed that FPV/R attaches to BHK-21 cells at 4°C 
and that the rate of attachment was unaffected by neutralization with polyclonal 
or monoclonal IgG directed to the HA, even in saturating amounts (unpublished 
data). However, virus that was neutralized with immune bile concentrate did not 
attach  in  significant amounts  to  BHK-21  cells  (Fig.  1).  To  be  certain  which 
constituent of the crude bile concentrate was responsible for the neutralization, 
we purified scIgA as described below. 
Purification of sclgA and Preparation of  Monomeric IgA.  Purified sclgA obtained 
using an anti-a chain affinity column retained antiviral activity without loss. By 
nonreducing PAGE  (Fig.  2),  scIgA  was  shown  to  consist of a  single protein 
species (Fig. 2 b) of ~400,000 mol wt, as expected (26). By differential reduction 
with 0.01  M BME, scIgA was separated into its major components, monomeric 
IgA (160,000  mol wt) and the secretory component (70,000 mol wt) (Fig.  2c). 
Monomeric IgA was isolated by using an affinity column to which rat anti-or 
chain antibody was coupled (Fig.  2a).  94 #g of sclgA yielded 46.8  pg of IgA. 
The HI titer per microgram of IgA was never <80%  of the titer of the scIgA 
from which it was derived. J  chain (15,000 mol wt; 26) was not detected on the 
gels. The neutralization activities of bile concentrate, scIgA, and IgA are shown 
in Table I. All failed to neutralize WSN. 
Mechanism  of Neutralization  by sclgA.  The attachment of virus neutralized 
with  purified  scIgA  is  compared in  Fig.  3  with  virus  neutralized  with  IgG. 
Preimmune scIgA did not restrict the attachment of virus to the BHK-21  cell 
monolayers, but attachment of virus neutralized by scIgA (to 96.5%) remained 
at the background level. Virus neutralized by IgG, on the other hand, attached 
to cells normally, as previously reported (11). 
Mechanism of Neutralization  by IgA.  To investigate whether the difference in 
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FIGURE  1.  Attachment of nonneutralized s~p-labeled FPV/R  and  virus  neutralized with 
immune bile concentrate to BHK-21  cell monolayers. Virus was first incubated for  1 h  at 
25°C  with  immune bile concentrate (O)  or  the  equivalent from nonimmunized rats  (A). 
Infectivity was neutralized only by the former to 97.5%. Virus-bile mixtures were chilled and 
100 ~l inoculated onto monolayers of BHK-21 cells in petri dishes (6 x  10  ° cells/dish) held on 
ice. Each  100 #1  contained 1.1  x  107  PFU,  320  HAU, and  1.98  x  l0  s cpm. At each time 
interval, monolayers were washed thoroughly with cold PBS before scraping the cells from 
the dish. The ordinate shows the amount of TCA-precipitated radioactivity attached to cells 
as a percentage of that inoculated. 202  NEUTRALIZATION  OF  INFLUENZA  VIRUS  BY  scIgA,  IgA,  AND  IgG 
FIGURE 2.  PAGE analysis  of sclgA (94 #g) before and after reduction with 0.01  M  BME. 
(Lane b) scIgA; (c) scIgA after treatment  with BME:  IgA monomers (160,000  mol wt) and 
secretory component (70,000  tool wt) can be seen; (a) monomeric IgA obtained after passing 
the sample  shown  in  c through  an  affinity column of anti-a chain  IgG.  Molecular weight 
markers are: (d) rabbit IgG, 150,000 mol wt; and (e) transferrin (Trfn), -~80,000 mol wt. The 
gel was stained for protein with Coomassie Brilliant Blue. 
TABLE  I 
Neutralization of FPV/R Influenza  Virus by Bile Concentrate, 
Purified sclgA, and Monomeric lgA 
Percentage neutralization* of: 
Immune samples  1 ×  107 PFU  1 ×  107 PFU 
FPV/R  WSN 
Bile concentrate  98.5  0 
Purified scIgA  96.5  0 
Purified monomeric IgA  98.5  0 
*  Relative to virus incubated with the appropriate control (bile concen- 
trate, purified sclgA, and monomeric scIgA) obtained from nonimmun- 
ized rats. These gave negligible neutralization. 
the ability of neutralized  virus to attach  to cells was related  to the structure of 
the neutralizing Ig, we determined the attachment of virus neutralized with IgA 
monomers  prepared  from  scIgA.  Fig.  4  shows  that  monomeric  IgA  did  not 
inhibit this process. Thus,  inhibition of attachment  by scIgA appears related to 
its dimeric structure  and not to any intrinsic  property of the Ig a  heavy chain 
itself. 
Association ofVirion RNA from Neutralized Virus with the Nucleus.  After attach- 
ment to the cell, virus is internalized  and uncoated;  the virus envelope compo- 
nents remain  in the cytoplasm while the transcriptase  complex of virion  RNA 
and associated proteins enter the nucleus (24).  By determining  the proportion 
of cell-associatedvirion  RNA that has entered nuclei,  we have shown (10,  11) 
that  these  early  stages  of infection  are  unchanged  after  the  virus  has  been 
neutralized with IgG. Similar experiments on the small fraction of virus neutral- 
ized by scIgA that attaches to cells (Fig.  5) show that virion RNA remained  in TAYLOR  AND  DIMMOCK  203 
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FIGURE  3.  Attachment  of nonneutralized  siP-labeled  FPV/R  and  virus  neutralized  with 
scIgA to BHK-21 cell monolayers. Virus was first incubated for 1 h at 25"C with neutralizing 
sclgA (nslga),  neutralizing IgG (nlgG), preimmune scIgA (pslga),  or preimmune lgG (plgG). 
Immune sclgA and  IgG neutralized virus by 96.5 and 99.5%, respectively. The subsequent 
procedure  is  described  in  Fig.  1,  except  that  each  100  #l  inoculated onto  the  cell  sheet 
contained initially 1.2 x  107 PFU, 36 HAU, and 1.2 x  10 ~ cpm. 
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FIGURE 4.  Attachment  of nonneutralized  S2p-labeled  FPV/R  and  virus  neutralized  with 
monomeric IgA to BHK-21  cell monolayers. Virus Was first incubated for 1 h at 25°C with 
neutralizing IgA (nlgA),  neutralizing IgG (nlgG), preimmune IgA (plgA), or preimmune IgG 
~plgG). Immune  IgA and  IgG  neutralized  virus  by  98.5  and  99.95%,  respectively. The 
subsequent procedure is described in Fig. 1, except that each 100 t~l inoculated onto the cell 
sheets contained initially 1.3 x  107 PFU, 47 HAU, and 2 X l0  s cpm. 
the cytoplasmic fraction whereas that from virus neutralized by IgG entered the 
nucleus, as previously described. It was therefore of particular interest to deter- 
mine if monomeric IgA, which had no effect on attachment of neutralized virus 
(see above), prevented  internalization  like  scIgA  or behaved like  IgG.  Fig.  6 
shows that  RNA from virus neutralized  by monomeric IgA accumulates in the 
nucleus at the same rate as RNA from nonneutralized virus. 
Attachment of  Nonneutralized and Neutralized 3~P-labeled FPV/R to BHK-21 Cell 
Monolayers  at 25 and 37 °C.  Although it is experimentally convenient to exam- 
ine the  early stages of infection at  4°C  (since  this  temperature  prevents virus 
macromolecular  synthesis),  it  is  possible that  virus  may  behave  differently  at 204  NEUTRALIZATION  OF  INFLUENZA  VIRUS  BY  sclgA,  IgA,  AND  IgG 
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FIGURE 5.  Association  of nonneutralized  and  neutralized  s2P-labeled  FPV/R  with  cyto- 
plasmic and  nuclear  fractions of BHK cells.  Virus was  neutralized with neutralizing scIgA 
(nslgA) or neutralizing IgG (nlgG) and inoculated as previously described in Fig. 1. nslgA and 
nlgG neutralized virus by 96.5  and  99.5%,  respectively. Each  I00 #1 inoculated contained 
initially 1.2 x  107 PFU, 36 HAU, and  1.9  x  10 ~ cpm. At the intervals indicated nuclear and 
cytoplasmic fractions were prepared. 
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FIGURE 6.  Kinetics of migration of virion RNA from cytoplasm to nucleus in cells inoculated 
with virus neutralized by monomeric IgA and nonneutralized virus. Virus was neutralized and 
inoculated as previously described in Fig.  1.  Immune IgA neutralized virus by 98.5%.  Each 
100 #l inoculated initially contained  1.3  x  107 PFU, 47  HAU, and 1.2 x  105 cpm. At the 
intervals indicated nuclear and cytoplasmic fractions were prepared. 
physiological temperatures. Fig. 7 shows that, although scIgA almost completely 
prevented attachment of neutralized virus at 4°C, attachment at 25 and 37°C 
was merely reduced by half. However, unlike virus neutralized by IgA (see above) 
or IgG (12), the majority of virion RNA remained in the cytoplasmic fraction 
(Fig. 8) and <5% RNA was taken up into the nuclei. TAYLOR  AND  DIMMOCK 
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FIGURE 7.  Attachment of nonneutralized and neutralized raP-labeled FPV/R to BHK-21 cell 
monolayers at  physiological temperature.  Virus  was  first incubated  for  1 h  at  25°C  with 
neutralizing scIgA (solid symbols) or preimmune scIgA (open symbols). The neutralizing scIgA 
reduced infectivity by 98%. Virus-antibody mixtures (100 #l) were then inoculated onto BHK- 
21  cells at 4, 25, and 37°C. Each  100 #1 initially contained  1.3  x  107 PFU, 316 HAU, and 
1.9 x  105 cpm. The percentage attachment was determined as previously described. 
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FIGURE 8.  Kinetics  of migraiion  of mP-virion  RNA  from  cytoplasm  to  nucleus  in  cells 
inoculated with virus neutralized by scIgA. Virus was neutralized and inoculated at 4, 25, and 
37°C as described in Fig. 7.  The immune scIgA neutralized virus by 98%.  Each  100 #1 of 
inoculum initially contained  1.3  x  107  PFU,  316  HAU, and  1.9  x  105 cpm.  Neutralizing 
scIgA at 40C (A), 25°C (m), and 37°C (@); preimmune scIgA at 40C (A), at 250C (1"7), and at 
37°C (O). 
Because the cytoplasmic fraction includes the plasma membrane, we could not 
tell if virus was attached to the outside of the cell or had been internalized.  The 
question was resolved by treating  with proteinase  K cells inoculated with virus 
neutralized  by scIgA.  This  released the  majority of virus attaching  at  25 and 
37°C (58 and 68.2%, respectively), demonstrating  that  the virus had not been 
internalized but remained attached to the outside of the cell. Treatment of cells 206  NEUTRALIZATION  OF  INFEUENZA  VIRUS  BY  sclgA,  IgA,  AND  IgG 
that were inoculated with virus treated with preimmune scIgA released no more 
than 8% cell-associated virus (Fig. 9). 
Discussion 
Studies of local immunity directed against infections of mucosal surfaces have 
been hindered in the past because of the problem of obtaining sufficient amounts 
of secretory IgA,  the  predominant  Ig  in  external  body  fluids  (27,  28).  We 
demonstrate here that this can be overcome by using bile from appropriately 
immunized rats. Such antibody was neutralizing in both the crude and purified 
form, and could discriminate between different strains of type A influenza virus 
(Table I). scIgA comprises ~70% of the total Ig in bile and about half the protein 
content (29). As a source of scIgA, bile has certain advantages over lung or nasal 
washings, which produce scIgA in a diluted form (16,  30), often contaminated 
with various cellular products, including other Igs and lymphokines (15, 16, 30). 
Further, immunochemical analysis has established (29, 30, 31) that scIgA from 
bile and respiratory secretions is identical. It has also been shown (32) that scIgA, 
stimulated by immunization of the gastrointestinal tract of human volunteers 
with inactivated influenza virus, is established in respiratory secretions. 
In this study our interest has been to determine the mechanism of neutraliza- 
tion  by  scIgA,  since,  in  the  respiratory  tract,  neutralizing  scIgA  is  a  major 
determinant of resistance to  reinfection with  influenza and other respiratory 
viruses (15,  16,  33,  34).  We also sought to compare this mechanism with the 
mechanism of neutralization by IgG.  Previous work (11) showed that  FPV/R 
neutralized by IgG attaches to and penetrates BHK-21  cells, at temperatures 
from 4 to 37 °C, at the same rate as nonneutralized virus. In contrast, the results 
of this study show that neutralizing scIgA almost completely inhibits attachment 
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FIGURE 9.  Release of sap-labeled virus neutralized by sclgA from BHK-21 cells by incubation 
with proteinase K. Cells were first inoculated with virus treated with preimmune scIgA (pslgA) 
or neutralizing sclgA (nslgA) as previously described. 100 ,I of  virus-antibody mixtures (initially 
containing 1.4 ×  107 PFU, 700 HAU, and 1.4 x  105 cpm) were inoculated onto BHK-21 cells 
at 25 or 37°C and incubated for 120 rain at these temperatures. Cells were then washed twice 
with cold PBS and incubated with 500 #1 proteinase K (2 #g/ml) or 500 #1 PBS for 60 min at 
4°C. The percentage sap released by proteinase K or by PBS was calculated relative to the  3~  total  P associated with cells before digestion was carried out. TAYLOR  AND  DIMMOCK  207 
at 4°C but acts far less  effectively at 25  and 37°C.  Despite attaching to cells, 
however, virus that was neutralized by scIgA was not internalized. Thus, neu- 
tralization by scIgA and IgG are qualitatively different phenomena. The nature 
of this difference was investigated by preparing IgA monomers from sclgA. IgA 
neutralized with comparable efficiency but did not affect attachment and pene- 
tration, which were indistinguishable from those effected by virus incubated with 
nonneutralizing IgA. 
The blocking of attachment of influenza virus by sclgA recalls earlier work 
with  bacterial  systems,  where the attachment to  cells of Vibrio  cholerae  (35), 
Streptococcus  sp. (36), and Escherichia coli (37) were inhibited by scIgA. However, 
the parallel  is  less  than perfect, since half the neutralized influenza virus did 
attach to cells; the reason why this virus is noninfectious is yet unknown. 
It seems likely that scIgA acts sterically to prevent attachment of neutralized 
virus to cells at  4°C.  Increased thermal agitation  is probably the reason why 
virus that was neutralized by scIgA attached to cells more efficiently at higher 
temperatures but,  since this did not lead to internalization of the virus,  such 
attachment may not have been correctly oriented. To expand this interpretation, 
we plan to determine the conformation of scIgA when it is bound to virus. Since 
scIgA comprises two Ig units linked by the SC and the J  chain (28), scIgA may 
bind either in a "hair pin" conformation, with both Ig units attached to the virus, 
or through only one of the units. The latter interpretation would approximately 
double the steric hindrance between cell and virus; it is supported by the failure 
of monomeric IgA to prevent attachment. However, the SC may also contribute 
to steric hindrance. 
Since we detected no difference in the early stages of infection between virus 
neutralized by IgA or by IgG and infectious virus, it may be that IgA and IgG 
have the same mechanism of neutralization.  Previously (12,  13),  we suggested 
that neutralization by IgG results from an effect on virion transcriptase, arising 
from conformational changes triggered by the binding of neutralizing antibody 
to the virus hemagglutinin, that is conveyed across the envelope to the transcrip- 
tase complex. 
Summary 
We have found that bile is a useful source of secretory IgA (sclgA) which can 
specifically neutralize influenza virus infectivity. Using purified scIgA, we com- 
pared the mechanism of neutralization with that mediated by IgA monomers 
(prepared from scIgA by differential reduction) and IgG. At 4°C,  scIgA pre- 
vented the attachment of neutralized virus, while neither monomeric IgA nor 
IgG had any affect on this process or on the subsequent stages of infection by 
which virion RNA accumulates in nuclei. At 25 and 37°C, scIgA permitted the 
attachment of approximately half the neutralized virus, but the virus was not 
internalized. Clearly, the neutralization depends on the character of the antibody 
used. scIgA may act by steric hindrance (with attachment or penetration, de- 
pending on temperature), whereas IgA and IgG neutralize infectivity at a stage 
subsequent to accumulation of the virus genome in the nucleus. 
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